

# Sara Pilotto

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8248517/sara-pilotto-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144 papers	2,232 citations	26 h-index	43 g-index
197 ext. papers	2,921 ext. citations	4 avg, IF	4.73 L-index

#	Paper	IF	Citations
144	Exercise oncology: It is time to make a change.. <i>Patient Education and Counseling</i> , <b>2022</b> ,	3.1	0
143	Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy?. <i>Nutrition</i> , <b>2022</b> , 98, 111637	4.8	1
142	SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 840783	5.3	0
141	Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 175, 103726	7	0
140	Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research. <i>European Journal of Oncology Nursing</i> , <b>2021</b> , 55, 102061	2.8	0
139	Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 169, 103536	7	0
138	Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.. <i>ESMO Open</i> , <b>2021</b> , 7, 100308	6	2
137	Psychological impact of Covid-19 pandemic on oncological patients: A survey in Northern Italy. <i>PLoS ONE</i> , <b>2021</b> , 16, e0248714	3.7	8
136	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2021</b> , 146, 74-83	7.5	8
135	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 650293	5.3	4
134	Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. <i>ESMO Open</i> , <b>2021</b> , 6, 100104	6	5
133	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 160, 103300	7	1
132	A multimodal approach to cancer-related cachexia: from theory to practice. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 819-826	3.5	4
131	How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 669786	5.3	4
130	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Molecular Pathology</i> , <b>2021</b> , 2, 207-222	0.4	
129	A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 3369-3384	4.4	2
128	Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , <b>2021</b> , 17, 2513-2527	3.6	0

127	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1583-1592	7.4	4
126	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 351-360	4.9	2
125	Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2574-2585	2.2	3
124	Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report. <i>Immunotherapy</i> , <b>2021</b> , 13, 971-976	3.8	2
123	Exercise prehabilitation in lung cancer: Getting stronger to recover faster. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 1847-1855	3.6	3
122	Exploring the role of respiratory microbiome in lung cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 164, 103404	7	6
121	Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus -paclitaxel for Advanced Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 688889	5.3	2
120	Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability. <i>Journal of Cancer Education</i> , <b>2021</b> , 1	1.8	0
119	Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study. <i>Breast</i> , <b>2021</b> , 60, 6-14	3.6	1
118	Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy?. <i>Acta Oncologica</i> , <b>2021</b> , 1-5	3.2	0
117	1701P Oncological patients' perception of infection risks and level of acceptance of protective measures during SARS-CoV-2 pandemic. <i>Annals of Oncology</i> , <b>2020</b> , 31, S1003	10.3	78
116	Aberrations in NSCLC: So Close Yet So Far.. <i>JCO Precision Oncology</i> , <b>2020</b> , 4, 1049-1051	3.6	
115	Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 5325-5334	3.1	10
114	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , <b>2020</b> , 12,	6.6	27
113	Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 531-542	3.5	2
112	Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 159-169	7.5	9
111	First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , <b>2020</b> , 130, 155-167	7.5	53
110	Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 148, 102862	7	14

109	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , <b>2020</b> , 50, 56-63	3.6	3
108	"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients. <i>PLoS ONE</i> , <b>2020</b> , 15, e0227846	3.7	5
107	Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. <i>ESMO Open</i> , <b>2020</b> , 5, e000689	6	4
106	Factors Influencing Physical Activity in Cancer Patients During Oncological Treatments: A Qualitative Study. <i>Integrative Cancer Therapies</i> , <b>2020</b> , 19, 1534735420971365	3	6
105	Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16769-e16769	2.2	1
104	EXPLORE EXERCISE LEVEL AND PREFERENCES IN PANCREATIC CANCER PATIENTS. <i>Medicine and Science in Sports and Exercise</i> , <b>2020</b> , 52, 485-486	1.2	
103	Effect of evidence-based nutrition educational intervention on adherence to dietary guidelines (ADG) and weight management among early-stage breast cancer (EBC) patients (pts): A prospective trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 12056-12056	2.2	
102	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer (NSCLC) overexpressing PD-L1: Early results of the FoRECATT Study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 9598-9598	2.2	
101	Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 294-301	3.6	1
100	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 146, 102858	7	28
99	Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?. <i>Oncologist</i> , <b>2020</b> , 25, e555-e569	5.7	41
98	High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 588862	5.3	4
97	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920968463	5.4	7
96	Exercise Levels and Preferences in Cancer Patients: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	16
95	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , <b>2020</b> , 150, 123-131	5.9	4
94	Physical Activity for Oncological Patients in COVID-19 Era: No Time to Relax. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa071	4.6	4
93	Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg. <i>Thrombosis Research</i> , <b>2020</b> , 194, 216-219	8.2	10
92	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 1-14.e3	4.9	10

91	ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 15-20	4.9	34
90	Infections and Immunotherapy in Lung Cancer: A Bad Relationship?. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 22,	6.3	7
89	Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report. <i>Future Science OA</i> , <b>2020</b> , 7, FSO659	2.7	3
88	Running with cancer A qualitative study to evaluate barriers and motivations in running for female oncological patients <b>2020</b> , 15, e0227846		
87	Running with cancer A qualitative study to evaluate barriers and motivations in running for female oncological patients <b>2020</b> , 15, e0227846		
86	Running with cancer A qualitative study to evaluate barriers and motivations in running for female oncological patients <b>2020</b> , 15, e0227846		
85	Running with cancer A qualitative study to evaluate barriers and motivations in running for female oncological patients <b>2020</b> , 15, e0227846		
84	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , <b>2019</b> , 11,	6.6	18
83	Muscle derangement and alteration of the nutritional machinery in NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 141, 43-53	7	10
82	Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e514-e516	4.9	6
81	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1651-1661	8.9	44
80	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. <i>Cancers</i> , <b>2019</b> , 11,	6.6	47
79	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , <b>2019</b> , 134, 121-126	5.9	1
78	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , <b>2019</b> , 105, 3-14	1.7	6
77	Listening understanding and acting (lung): focus on communicational issue in thoracic oncology.. <i>Translational Cancer Research</i> , <b>2019</b> , 8, S16-S22	0.3	
76	P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET). <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, S644	8.9	5
75	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 7652014	4.3	21
74	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , <b>2019</b> , 11, 921-930	3.8	5

73	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e186-e194	4.9	27
72	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 472, 567-577	5.1	41
71	Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 568-575	8.9	9
70	Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease. <i>Clinical Respiratory Journal</i> , <b>2018</b> , 12, 1150-1159	1.7	2
69	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 93-104	4.9	31
68	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 191-198	4.9	1
67	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. <i>Carcinogenesis</i> , <b>2018</b> , 39, 971-980	4.6	32
66	Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 129, 54-66	7	19
65	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 937-945	5.4	10
64	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. <i>Cancers</i> , <b>2018</b> , 10,	6.6	78
63	Role of mTOR Signaling in Tumor Microenvironment: An Overview. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	74
62	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, S1564-S1580	2.6	35
61	Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?. <i>Seminars in Oncology</i> , <b>2018</b> , 45, 176-180	5.5	3
60	Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 497-506	5.4	4
59	Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors. <i>Cancer Genetics</i> , <b>2017</b> , 210, 28-33	2.3	2
58	Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , <b>2017</b> , 35, 21-26	3.6	12
57	OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S266-S267	8.9	4
56	ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes. <i>Cancer Biomarkers</i> , <b>2017</b> , 18, 215-220	3.8	3



55	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. <i>Expert Review of Molecular Diagnostics</i> , <b>2017</b> , 17, 1055-1069	3.8	19
54	Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 60, 1-11	14.4	17
53	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	89
52	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. <i>Journal of Pathology</i> , <b>2017</b> , 241, 488-500	9.4	122
51	MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. <i>Annals of Translational Medicine</i> , <b>2017</b> , 5, 2	3.2	32
50	A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 539-539	2.2	
49	Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis. <i>Scientific Reports</i> , <b>2016</b> , 6, 22982	4.9	13
48	Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. <i>Pulmonary Therapy</i> , <b>2016</b> , 2, 1-18	3	2
47	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. <i>Oncologist</i> , <b>2016</b> , 21, 283-91	5.7	35
46	Tubulin inhibitors in non-small cell lung cancer: looking back and forward. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1113-29	4	18
45	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 98, 254-63	7	1
44	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 30-6	8.7	39
43	Cellular and molecular biology of small cell lung cancer: an overview. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 2-15	4.4	38
42	Propensity score analysis investigating the role of hormonal maintenance (HM) for advanced breast carcinoma with luminal subtype (ABC-Lum): Implication for prognostic modeling, post-progression and conditional survival (PPS/CS).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 545-545	2.2	
41	Cut-off analysis and prognostic relevance of Ki67 for resected early stage pure invasive lobular breast carcinoma (ILC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 544-544	2.2	
40	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. <i>Respiratory Research</i> , <b>2016</b> , 17, 105	7.3	9
39	Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. <i>Breast</i> , <b>2016</b> , 29, 24-30	3.6	8
38	Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2016</b> , 35, 50	12.8	4

37	Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over?. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 635-8	5.9	
36	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 2253-2266	4	22
35	The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 1359-70	5.4	11
34	Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , <b>2015</b> , 88, 319-24	5.9	4
33	An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1143-61	5.9	5
32	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 93, 50-9	7	11
31	Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening. <i>EBioMedicine</i> , <b>2015</b> , 2, 782-3	8.8	
30	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. <i>Scientific Reports</i> , <b>2015</b> , 5, 17499	4.9	40
29	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0130142	3.7	339
28	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1341-1348	8.9	13
27	Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2015</b> , 15, 15-25	2.2	5
26	Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 12783-95	3.3	44
25	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , <b>2015</b> , 4, 704-12	4.4	7
24	Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2015</b> , 15, 307-13	2.2	10
23	Platelets and their role in cancer evolution and immune system. <i>Translational Lung Cancer Research</i> , <b>2015</b> , 4, 713-20	4.4	11
22	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , <b>2015</b> , 4, 721-7	4.4	22
21	Melanoma: oncogenic drivers and the immune system. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 265	3.2	15
20	Other targeted drugs in melanoma. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 266	3.2	5



19	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 535-49	4.1	22
18	ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 729-32	8.9	39
17	Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 847-56	14.4	15
16	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 90, 135-45	7	11
15	High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. <i>Gastric Cancer</i> , <b>2014</b> , 17, 442-9	7.6	45
14	Prognostic impact of alternative splicing-derived hMEN1 isoforms in resected, node-negative, non-small-cell lung cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 11054-63	3.3	23
13	Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 3958-72	3.3	10
12	Prognostic value of ALK gene copy number (GCN) status for resected and metastatic non-small-cell lung cancer (NSCLC): A retrospective analysis of 205 patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e19059-e19059	2.2	
11	Clinical meta-analyses of targeted therapies in adenocarcinoma. <i>Targeted Oncology</i> , <b>2013</b> , 8, 35-45	5	3
10	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , <b>2013</b> , 8, 1381-97	6.2	6
9	PROFILING non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 597-608	4	6
8	Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors. <i>Lung Cancer Management</i> , <b>2013</b> , 2, 89-92	2.6	
7	Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, e105-6	8.9	13
6	Could a biomarkers-based patients' selection help to plan a clinical trial with targeted agents (TA) for metastatic renal cell carcinoma (mRCC)? Interaction and power analysis of randomized trials (RCTs).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 399-399	2.2	
5	Targeted agents (TA) for advanced solid tumors (AST): What is the likelihood of being helped or harmed (LHH)? Assessing the clinical impact of therapies with FDA/EMA approval.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e17555-e17555	2.2	0
4	How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e16053-e16053	2.2	
3	Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 630-630	2.2	
2	Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 115	12.8	23

- 1 Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer. *Expert Review of Anticancer Therapy*,1-11 3.5 0